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Cyanine dye mediated mitochondrial targeting
enhances the anti-cancer activity of
small-molecule cargoes†
Alexander R. No¨dling, ‡a Emily M. Mills,‡a Xuefei Li,a Davide Cardella,a
Edward J. Sayers, b Shih-Hsiung Wu,cd Arwyn T. Jones, b Louis Y. P. Luk a
and Yu-Hsuan Tsai *a
Organelle-specific delivery systems are of significant clinical interest.
We demonstrate the use of common cyanine dyes Cy3 and Cy5 as
vectors for targeting and delivering cargoes to mitochondria in cancer
cells. Specifically, conjugation to the dyes can increase cytotoxicity by
up to 1000-fold.
Mitochondria are important subcellular organelles for energy
production in eukaryotic cells and play critical roles in human
health and disease.1 As dysregulation of mitochondria is associated
with a variety of human diseases,2 vectors delivering therapeutics or
biochemical probes to this organelle has significant clinical
interest.3–5 A few molecular entities have been identified as being
mitochondria targeting,4–7 including triphenylphosphonium
cations8,9 and designer peptides.10,11 It is generally accepted that
molecules combining hydrophobic and cationic motifs may
exhibit some degree of mitochondrial targeting due to the
negative membrane potential (ca. 90 to 150 mV in mito-
chondrial matrix compared to cytosol).8 Nevertheless, development
of chemical entities that can both deliver cargo tomitochondria and
report their subcellular location simultaneously is still in its infancy.
Cy3 and Cy5 (Fig. 1a) are commercially available cationic
cyanine dyes. They have been commonly used to label mole-
cules for cell fluorescence studies including as a Fo¨rster reso-
nance energy transfer (FRET) pair.12 As a FRET pair, excitation
of Cy3 (554 nm) leads to fluorescence emission by Cy5 (666 nm)
when the two fluorophores are in close proximity. These dyes
are relatively small and hydrophobic yet are highly delocalised
cations. There is also evidence suggesting that they tend to locate
to mitochondria when incubated with cells at concentrations
over 1 mM,13–18 thus offering them as potential mitochondrial
targeting agents. Indeed, other heptamethine dyes have found
sporadic usage as mitochondrial probes or delivery vectors.19–21
However, the full potential of Cy3 and Cy5 for mitochondria
targeting and delivery has not been explored. Here, we illustrate
that Cy3 and Cy5 are mitochondria targeting as single entities or
conjugates and can deliver a variety of structurally diverse
molecules (e.g. peptide, heterocycle, metallocomplex) to mito-
chondria to exert cellular effects. Moreover, mitochondrial targeting
and delivery capacity is more prominent in cancer cells.
To examine their mitochondria targeting ability, HeLa cells
were incubated with 10 mM Cy3, Cy5 or Cy3–Cy5 (Fig. 1a and b)
followed by live-cell confocal imaging. Cy3–Cy5 was chosen to
investigate if having two fluorophores would enhance uptake
and targeting effect. This is of interest for designing Cy3–Cy5-
based FRET pairs as theranostic targeting vectors. For all three
constructs, the observed filamentous staining22 was highly
indicative of mitochondrial accumulation (Fig. 2). The subcellular
localisation pattern of these compounds was shown to be concen-
tration independent (Fig. S1, ESI†), and there was no evidence of
nuclear localisation (Pearson’s correlation coefficients o0.15,
Fig. 2 and Fig. S2, ESI†) or cytosolic staining. On the other hand,
Pearson’s coefficients40.85 were observed with both Cy3 and Cy5
when cells were subsequently incubated with MitoTracker Green
Fig. 1 Structure of compounds used in this study. (a) Cy3 and Cy5. (b)
Cy3–Cy5 and Cy3–Cy5-R8. (c) Dye conjugates. Synthetic schemes and
procedures are in the ESI.†
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before imaging (Fig. S3, ESI†), confirming the selective mito-
chondrial localisation. However, sequential incubation of cells
with Cy3–Cy5 and MitoTracker Green bizarrely showed a different
fluorescent pattern when compared to cells that were treated with
either molecule alone or as a non-covalent mixture (Fig. S4, ESI†).
It is likely that the higher lipophilicity of Cy3–Cy5 promotes its
propensity for aggregation.23–25 Indeed, lower Pearson’s correlation
coefficients were also obtained when treating cells with a mixture
of Cy3 and Cy5 than either Cy3 or Cy5 alone with MitoTracker
(Fig. S4, ESI†), suggesting hydrophobic interactions between
these molecules. Hence, application of Cy3–Cy5 as a mito-
chondrial targeting vector is less desirable compared to either
Cy3 or Cy5. Nevertheless, it is clear that all constructs preferentially
accumulated in mitochondria.
As the mitochondrial membrane potential is the driving force
for most cationic, lipophilic mitochondrial targeting molecules,8
we investigated if the sub-cellular localisation of cyanine dyes
depends on the membrane potential. Fixation renders cells
permeable to small molecules with a resulting collapse of the
mitochondrial membrane potential. While MitoTracker Green
contains functional groups for covalent crosslinking to mito-
chondria, such functionalities do not exist in Cy3. Indeed, little
change of fluorescent pattern was observed for MitoTracker
Green after fixing the cells with paraformaldehyde,26 whereas
colocalisation of Cy3 with MitoTracker Green was lost after cell
fixation (Fig. 3 and Fig. S5, ESI†). Similarly, when carbonyl
cyanide m-chlorophenyl hydrazone (CCCP), a known mitochondrial
depolarization agent,15 was added into cells treated with Cy3, the
filamentous staining rapidly disappeared. Nevertheless, removal of
CCCP from the culture media recovered the membrane potential
and restored the filamentous mitochondrial staining for Cy3 after
1 h (Fig. 3). These results indicate that the membrane potential is
critical for mitochondrial targeting of the tested cyanine dyes.
A crucial factor in the design of drug delivery vectors is the
knowledge of the respective uptake mechanism. Some small
molecules can enter cells by passive diffusion, and this was
confirmed for Cy3, Cy5 and Cy3–Cy5 by performing the uptake
experiments at 4 1C (Fig. S6 and S7, ESI†), at which no ATP-
dependent activity (e.g. endocytosis) takes place. We then examined
if cyanine dyes can influence the subcellular localisation and/or the
uptake mechanism of a molecule. We and others have explored the
potential cell delivery capability of R8, a short cell-penetrating
peptide of eight consecutive arginine residues.27–29 Small-molecule
cargoes conjugated to R8 are normally taken up by cells via
endocytosis at low concentration (o10 mM), but at higher
conjugate concentration (Z10 mM) cytosolic delivery through
passive diffusion of the conjugate can also be observed.30
Upon conjugation of R8 to cyanine dyes, the behaviour of
the resulting Cy3–Cy5-R8 (Fig. 1b) was examined by confocal
microscopy experiments using HeLa cells treated with different
concentrations (1, 2.5 or 10 mM) of Cy3–Cy5-R8 at either 4 or
37 1C. At 4 1C, Cy3–Cy5-R8 was able to enter cells only at 10 mM
but not at 2.5 mM (Fig. S6, ESI†), indicating passive diffusion of
Fig. 2 Representative (N = 10) confocal microscopy images of HeLa cells
treated with 10 mM of Cy3, Cy5, Cy3–Cy5 or Cy3–Cy5-R8 in the absence
or presence of 10% serum at 37 1C for 1 h before imaging. Excitation
wavelength for Hoechst, Cy3, and Cy5 is 405, 543, and 633 nm, respectively.
Scale bars denote 25 mm.
Fig. 3 The membrane potential determines subcellular localisation of
Cy3. (a and b) HeLa cells were stained with Mito-Tracker Green and Cy3
and imaged before (a) and after (b) fixation by paraformaldehyde. See
Fig. S5 (ESI†) for the correlation analysis. (c) Cy3-stained HeLa cells in
DMEM containing 10% FBS were treated with 20 mM CCCP for 6 min (from
t = 0 to t = 6) and washed to remove CCCP. Cells were then incubated in
fresh FBS-containing DMEM (from t = 6), and images were taken approxi-
mately 10 and 55 min afterwards (t = 16 and t = 60, respectively).
Representative (N = 2) confocal microscopy images are shown here.
FL = Fluorescence.
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this conjugate only taking place at 10 mM but not lower
concentrations. This observation is in agreement with the
literature.30 While only punctuated fluorescence resembling
endolysosomal localisation was observed with 2.5 mM Cy3–
Cy5-R8 at 37 1C (Fig. S7 and S8, ESI†), both punctuate and
filamentous fluorescence in the cytoplasm were observed when
increasing the conjugate concentration to 10 mM (Fig. 2). How-
ever, the fluorescence intensity of Cy3–Cy5-R8 was influenced
by the presence of serum in the culture media unlike the other
constructs tested. This is likely due to binding of R8 to serum
proteins, thus reducing the extracellular concentration of free
conjugates and capacity for cell entry.31 Nevertheless, the
filamentous fluorescence observed with 10 mM Cy3–Cy5-R8 at
37 1C is indicative of mitochondria accumulation, which
is supported by moderate Pearson’s correlation coefficients
(0.4–0.8) of Cy3–Cy5-R8 and MitoTracker (Fig. S4, ESI†).
Our results indicate that conjugation to cyanine dyes affected
the subcellular localisation of the conjugate but not the uptake
mechanism. The mitochondria localisation observed with 10 mM
Cy3–Cy5-R8 at 37 1C most likely resulted from the fraction of
Cy3–Cy5-R8 that first translocated to the cytosol by passive
diffusion through the plasma membrane. Once in the cytosol,
the conjugate was directed to the mitochondria. The ability of
cyanine dyes to alter the subcellular localisation of R8 is unique.
It was reported that conjugation of a cell-penetrating peptide with
a mitochondrial targeting triphenylphosphonium cation did not
cause mitochondrial accumulation of the conjugate.32 Thus,
cationic cyanine dyes may be superior mitochondrial targeting
entities than triphenylphosphonium cations.
Having observed and studied the subcellular localisation
properties and the cellular uptake mechanisms, we set to evaluate
if Cy3 and Cy5 can be used to deliver different cargoes to
mitochondria to mediate a cellular effect. Three different model
cargoes were selected (Fig. 1c) to assess the effect of mitochondrial
targeting by conjugation to a cyanine dye. These cargoes are a
peptide (KLA), a heterocyclic compound (Cip), and a metallo-
complex (CPT). They represent three important classes of drugs
in clinical application, and the molecular targets of these cargoes
are believed to be inmitochondria.33–39 KLAKLAKKLAKLAK (KLA) is
a proapoptotic, antimicrobial peptide.33,34 Ciprofloxacin (Cip) is a
fluoroquinolone with antibiotic activity but can also cause damage
to mitochondrial DNA, showing cytotoxicity to eukaryotic cells.35–38
CPT is a metal complex and a derivative of carboplatin (a widely
used anti-cancer drug) that impairs mitochondrial function and
leads to apoptosis.39 The synthesis of all drug conjugates proved to
be rapid and straightforward through simple coupling of the free
carboxylic acid of the cyanine dyes. Although conjugates containing
both Cy3 and Cy5 may enhance their mitochondrial localisation,
they may have higher propensity for aggregation. Therefore, we
refrained from using conjugates containing two cyanine dyes for
delivering mitochondrial-acting cargoes.
To assess the effect of mitochondrial targeting by conjugation
to Cy3, we first determined the viability of HeLa cells after treatment
with either Cy3, the unconjugated cargo, a mixture of the unconju-
gated cargo and Cy3, or the respective conjugate. The individual
EC50 values were calculated by curve fitting (Fig. 4 and Fig. S9, ESI†).
All conjugates containing a covalent linkage of Cy3 and the cargo
molecule are more cytotoxic than either simple mixtures of Cy3
and the unconjugated cargo or the cargo alone. Compared to
the parent cargo, toxicity increases from 100-fold (EC50 = 0.8 mM
vs. 85 mM for Cy3-CPT vs. CPT) to 1000-fold were observed
(EC50 = 4 mM vs. 4020 mM for Cy3-KLA vs. KLA). While Cy3 alone
exhibits cytotoxicity (EC50 = 26 mM), a 5- to 30-fold enhancement
was observed upon covalent conjugation to the cytotoxic cargo.
Confocal microscopy studies of the cargo conjugates were
performed to probe the dual functionality of the cyanine dyes to
act as mitochondrial targeting/delivery vectors and as diagnostic
tools to track cargo localisation (Fig. S10, ESI†). Clear colocalisation
of Cy3-KLA with MitoTracker Green was observed upon sequential
incubation of HeLa cells with MitoTacker and the conjugate
(Pearson’s correlation coefficient = 0.830), confirming the delivery
ofCy3-KLA to themitochondria. Although conjugation of a bioactive
molecule to a vectormay lead to a decrease in its biological activity40
(e.g. due to lowering the binding affinity to the cellular target), this
does not seem to be the case for Cy3 conjugation which significantly
increases the cytotoxicity (Fig. 4). Nevertheless, it would be interest-
ing to investigate whether using a cleavable linker (e.g. disulphide)41
that releases the bioactive molecule upon reaching the subcellular
target can further enhance the potency of this system.
Moreover, Cy3 conjugates were found to be more toxic in
cancer than non-cancer cells (Fig. S9, ESI†). Specifically, EC50
values of Cy3-KLA are significantly lower (po 0.01) in cancer cell
lines (4.0, 1.7, 1.9 mM in HeLa, KB, MCF7) than non-cancer cell
lines (11.1, 12.0 mM in HEK, 10T1/2). Up to 10-fold difference in
potency was also observed with Cy3-CPT (EC50 = 0.8 mM inHeLa vs.
11.1 mM in HEK). Selectivity in different cells could be due to the
more negative mitochondrial membrane potential in cancer cells
than non-cancer cells.42–44 However, HEK and 10T1/2 cells are
immortalised and should not be considered as healthy cells.
Primary cells or in vivo studies are now required to further
determine the exact therapeutic window for further translational
studies of the conjugates between cancer and healthy cells. Lastly,
Cy5 can also be used as a mitochondrial targeting and delivery
vector as it decreases the EC50 of KLA upon forming the conjugated
Cy5-KLA, demonstrating the general applicability of simple cationic
cyanine dyes as targeting entity for bioactive molecule delivery.
Fig. 4 Toxicity of cyanine dye conjugates in mammalian cells. (a) Repre-
sentative cell viability curves are shown. Error bars represent the standard
deviation of three biological replicates (cells of different passages), and
each biological replicate includes three technical replicates (cells of the
same passage). (b) The EC50 values of different molecules and their
cyanine dye conjugates were quantified using cell viability assays. The 
values represent the standard error of the curve fitting using Origin 2017.
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In conclusion, our work demonstrated the use of common
cyanine dyes as novel vectors for targeting drugs to mitochondria
in cancer cells. In addition, due to the fluorescence properties
of cyanine dyes, theranostics and novel molecules for photo-
dynamic therapy can be derived and investigated. Nevertheless,
our results also highlight how lipophilic cationic dyes as
fluorescent labels may influence the cellular fate of labelled
compounds in fluorescence studies.
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